Pfizer is a bottoming stock that will pay you to wait for the comeback, says Carter Worth

Former pharmaceutical champion Pfizer (PFE) , down 52% from its December 2021 all-time high, is judged to be in the throes of a “bearish-to-bullish” Reversal. Once the most valuable large-cap pharma stock in the world, Pfizer has suffered setback after setback the past three years and at present, at $29.30 a share, is trading now only slightly above its March 2020 Covid low of $26.32. Of late, the stock “acts well” as the old-time technical expression goes, exhibiting bullish price-volume correlation and good relative strength to its peers in the S & P 500 Pharmaceuticals Industry Group. Pfizer, the laggard the past year: Is now… Pfizer, the leader the past month: By our work, PFE represents a compelling “value play”. And with a 5.73% dividend yield, one “gets paid” to wait as the stock continues to bottom. -Carter Braxton Worth For actionable recommendations via email and live nightly videos become a member at worthcharting.com DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.